<DOC>
	<DOCNO>NCT01576328</DOCNO>
	<brief_summary>This study conduct assess overall safety tolerability single intravenous infusion three dos Mesenchymal Precursor Cells versus Placebo subject Type 2 Diabetes inadequately control Metformin .</brief_summary>
	<brief_title>Safety Study Mesenchymal Precursor Cells Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Key Male female subject ≥ 18 ≤ 80 year old Subjects diagnose type 2 diabetes least one year prior Screening receive stable , therapeutic dose metformin &gt; 1500 mg/day accord local prescribe information least 3 month prior Screening high tolerate dose &gt; 1000 mg/day document subject 's history HbA1c &gt; 7.0 % &lt; 10.5 % Screening Cpeptide &gt; 0.8 ng/mL Screening Body mass index ( BMI ) &gt; 22 &lt; 45 kg/m2 Screening Body weight &lt; 150 kg Screening Key Prior participation stem cell study Women pregnant , intend become pregnant study period currently lactate History active substance abuse ( include alcohol ) within past 2 year . Current alcohol abuse define daily consumption &gt; 3 alcoholic beverage . Current cigarette smoking &gt; 10 cigarette per day Severe hypoglycemia ( defined require third party assistance ) repeat and/or frequent hypoglycemia episode ( &gt; 2 episodes/week ) within one month prior Screening Patients receive treatment type 2 diabetes diet exercise alone , insulin therapy within 6 month Screening except use transiently &lt; 7 day intercurrent illness antidiabetic medication except metformin within 3 month Screening Any concurrent medical condition/disorder clinically symptomatic cardiovascular , gastrointestinal ( include pancreatitis ) , renal , hematological , pulmonary , acute chronic infectious disease , active retinal disease , disorder Investigator 's opinion would interfere subject 's ability complete trial , would require administration treatment could affect interpretation safety efficacy variable would preclude safe involvement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>